San Francisco Business Times -- by Ron Leuty -- The drug industry’s yawning “valley of death” -- where drug compounds often die from underfunding -- is forcing biotechs, pharmaceutical companies, investors and research institutes to eagerly seek new ways to affordably and quickly push drugs through the development process.
